Metropolitan Life Insurance Co. NY Has $132,000 Stake in NanoString Technologies Inc (NSTG)

Metropolitan Life Insurance Co. NY increased its position in NanoString Technologies Inc (NASDAQ:NSTG) by 430.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,893 shares of the biotechnology company’s stock after purchasing an additional 7,218 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in NanoString Technologies were worth $132,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc boosted its stake in shares of NanoString Technologies by 28.4% in the third quarter. Legal & General Group Plc now owns 3,800 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 840 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in NanoString Technologies in the fourth quarter valued at $151,000. AQR Capital Management LLC acquired a new stake in NanoString Technologies in the third quarter valued at $294,000. MetLife Investment Advisors LLC raised its holdings in NanoString Technologies by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 17,579 shares of the biotechnology company’s stock valued at $313,000 after acquiring an additional 6,249 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in NanoString Technologies by 21.5% in the third quarter. Alliancebernstein L.P. now owns 19,800 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 3,500 shares in the last quarter. Institutional investors and hedge funds own 87.94% of the company’s stock.

NSTG has been the topic of several recent analyst reports. BidaskClub raised shares of NanoString Technologies from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 5th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $35.00 price target on shares of NanoString Technologies in a report on Friday, March 8th. ValuEngine raised shares of NanoString Technologies from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 2nd. Finally, Zacks Investment Research cut shares of NanoString Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. NanoString Technologies has an average rating of “Buy” and an average target price of $22.80.

In other NanoString Technologies news, insider R Bradley Gray sold 20,000 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $22.28, for a total transaction of $445,600.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lifesciences Ii L.P. Clarus sold 2,000,000 shares of the stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $21.62, for a total transaction of $43,240,000.00. The disclosure for this sale can be found here. Insiders have sold 2,088,141 shares of company stock worth $43,896,351 over the last three months. 20.90% of the stock is owned by corporate insiders.

NSTG opened at $23.71 on Friday. The firm has a market capitalization of $737.03 million, a P/E ratio of -8.53 and a beta of 1.30. The company has a debt-to-equity ratio of 1.58, a quick ratio of 2.75 and a current ratio of 3.05. NanoString Technologies Inc has a 12-month low of $8.97 and a 12-month high of $31.14.

NanoString Technologies (NASDAQ:NSTG) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.18). The company had revenue of $30.03 million during the quarter. NanoString Technologies had a negative net margin of 72.52% and a negative return on equity of 252.59%. As a group, equities research analysts anticipate that NanoString Technologies Inc will post -2.36 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Has $132,000 Stake in NanoString Technologies Inc (NSTG)” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/metropolitan-life-insurance-co-ny-has-132000-stake-in-nanostring-technologies-inc-nstg.html.

NanoString Technologies Profile

NanoString Technologies, Inc engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway.

Featured Story: How to interpret a stock’s beta number

Want to see what other hedge funds are holding NSTG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NanoString Technologies Inc (NASDAQ:NSTG).

Institutional Ownership by Quarter for NanoString Technologies (NASDAQ:NSTG)

Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.